16Jun
Diligence Clauses and the Management of Uncertainty in Life Sciences Agreements
In times of uncertainty and disruption, setting expectations for performance with business partners and contractual counterparties can be more complicated than ever. Companies that develop drugs, biologics and medical devices have considerable...
By:
Skadden, Arps, Slate, Meagher & Flom LLP
Related
After weeks or months of remote work or closed operations, businesses are understandably eager to re...
Read More >
Three recent antitrust merger reviews involving nascent competition demonstrate enforcers are paying...
Read More >
New York State will vastly expand the scope of its Equal Pay Act to cover all characteristics protec...
Read More >
The increasing accessibility of digital media has enabled businesses to become not only readers, but...
Read More >
In Skye Mineral Investors LLC v. DXS Capital (U.S.) Limited, et al., the Delaware Court of Chancery ...
Read More >
Seyfarth Synopsis: In complex class actions, courts have looked to Rule 23 to authorize class action...
Read More >